Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Verywell Health on MSN1d
Navigating Care Through Every Phase of Metastatic Breast CancerIf you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
A breast cancer diagnosis often arrives as a profound turning point, bringing uncertainty and complex emotions. While the ...
Woman&Home on MSN14h
"Cancer was just a job, until it happened to me" – a doctor shares her moving breast cancer storyAuthor, speaker and health content creator Dr Liz O’Riordan shares her journey from consultant breast surgeon to cancer ...
Verywell Health on MSN1d
8 Ways to Combat Isolation With a Metastatic Breast Cancer DiagnosisSeveral studies show that isolation is very common among those diagnosed with metastatic breast cancer. However, there are ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...
Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback